A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients.

Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2018

At a glance

  • Drugs Vancomycin (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms AVAIL
  • Sponsors Savara Pharmaceuticals
  • Most Recent Events

    • 09 May 2018 According to Savara Pharmaceuticals media release, enrollment was at 62 patients at the end of Q1 and complete enrolment is expected in Q1 2019. Topline data anticipated in H2 2019.
    • 25 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 07 Jun 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top